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Background: The control of daytime and nighttime symptoms is an important measure of effec-
tiveness of asthma therapy, especially, when administered once-daily.
Objective: To evaluate the efficacy of evening and morning administrations of mometasone
furoate administered via a dry powder inhaler (MF-DPI) 400 mg once-daily (QD) to show
equivalence.
Methods: Open-label, randomized, parallel-group study in adult patients with mild to moder-
ate asthma with a 3-month history of ICS use. Patients received MF-DPI 400 mg QD either in
the morning (AM) or evening (PM) for 12 weeks. The primary measure was the change in asthma
symptoms from baseline to week 12. Secondary outcomes included response to treatment, ad-
herence, inhaler device evaluation, use of rescue medication, urinary cortisol levels, and dif-
ferential white blood cell count.
Results: A total of 1537 patients were randomized; the efficacy population comprised 543 and
479 patients in the MF-DPI QD morning and evening groups, respectively. Mean improvements
from baseline in daytime symptom scores at week 12 with morning and evening administration
of MF-DPI 400 mg were 0.11 0.59 and 0.12 0.68, respectively (95% CI, 0.095 to 0.061)
and the corresponding improvements in nighttime symptom scores were 0.08  0.59 and
0.07 0.50, respectively (95% CI, 0.067 to 0.068). Use of rescue medication was the same
in both groups (1 puff/day). MF-DPI QD was well tolerated regardless of time of administration.3 22 4781; fax: þ46 13 22 4773.
lio.se (O. Zetterstro¨m).
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dosing of MF-DPI 400 mg QD. A better effect of evening dosing compared to morning dosing
found in previous double-blind placebo-controlled studies could not be confirmed.
ª 2008 Elsevier Ltd. All rights reserved.Introduction
Circadian rhythms play a key role in many physiologic
processes, such as the sleepewake cycle, regulation of
body temperature and hormone secretion, as well as auto-
nomic nervous system activity.1 Diurnal variations in lung
function have been observed in both healthy individuals
and patients with asthma. The highest peak expiratory flow
(PEF) and forced expiratory volume in 1 s (FEV1) occur at
about 4 PM and trough values occur at about 4 AM.2 Nocturnal
asthma is defined as deterioration of asthma at night; that is,
asthma attacks at night with awakening caused by increase in
symptoms, need for medication, and/or worsening of lung
function.1 The severity of the nocturnal decline in lung
function correlates with impairment of daytime functioning.2
Inhaled corticosteroid (ICS) is the basic pharmacological
treatment for control of mild, moderate, and severe
persistent asthma.3,4 A portion of the ICS is absorbed into
the systemic circulation from the airways/lungs and the
ICS swallowed.5 Suppression of endogenous cortisol levels
following ICS therapy is indicative of an effect on the hypo-
thalamicepituitaryeadrenal (HPA) axis and represents
undesired systemic activity. Meibohm and colleagues
reported that once-daily (QD) administration of an ICS in
the afternoon or early evening is associated with minimum
cumulative cortisol suppression and, therefore, minimal
systemic adverse effects.6 Several other studies have re-
ported that QD ICS administration during the early evening
provided equivalent efficacy to 4 times daily dosing, with-
out increasing adverse effects.7,8
Mometasone furoate administered via a dry powder
inhaler (MF-DPI) is an ICS approved for once-daily evening
administration (i.e., QD PM dosing) as controller therapy for
patients with persistent asthma.9 Several studies have
reported that QD PM administration of MF-DPI 200 mg or
400 mg improved lung function and reduced daytime and
nighttime asthma symptoms among patients previously de-
pendent on twice-daily ICS therapy.10,11 In addition, Bensch
and colleagues reported that MF-DPI 200 mg QD in the even-
ing was effective in ICS-naive patients.12 A double-blind,
placebo-controlled study that compared morning and even-
ing dosing regimens of MF-DPI 200 mg QD in patients with
mild to moderate persistent asthma found that evening
dosing was the more effective regimen without a significant
effect on the HPA axis.10
Previous studies with MF-DPI were either placebo- or
active-controlled with the primary objective of measuring
the change in FEV1. None of the previous studies were de-
signed with the primary objective of comparing the efficacy
of evening versus morning administration of MF-DPI using
patient-reported outcomes. The present study was designed
to explore the differences between evening andmorning ad-
ministration of MF-DPI 400 mg QD in patients with persistent
asthma using subjective patient-reported symptom scores asthe primary outcome parameter and in a subgroup of pa-
tients study the influence of MF-DPI 400 mg QD morning or
evening on 24 h urinary cortisol amount.
Patients and methods
This was a multicenter, randomized, open-label, parallel-
group study. Patients were enrolled at 120 study sites in
Norway (28 sites), Sweden (66) and Finland (26). The study
protocol was reviewed and approved by the appropriate
ethics committees in each country. The study was
conducted in accordance with Good Clinical Practice and
in compliance with the World Medical Association Declara-
tion of Helsinki. Patients provided written informed
consent before the start of any study-related procedure.
Patients
Patients were at least 18 years of age with a diagnosis of mild
tomoderate asthma and a history of daily ICS use for at least 3
months, the last 30 days of which included the use of a stable
dose.Themaximumdailydoseofprevious ICS therapyallowed
was 500 mg fluticasone propionate, 800 mg budesonide, and
1000 mg beclomethasone dipropionate. Patients were ex-
cluded if they were pregnant or breast-feeding; had respira-
tory disease other than asthma (e.g., chronic obstructive
pulmonary disease); had an asthma-related hospital admis-
sion within the previous 3 months or more than once within
the previous 6months; had unstable asthma; were on ventila-
tor support for respiratory failure within the previous 5 years;
had oropharyngeal candidiasis at baseline; or had clinically
significant cardiovascular, neurologic, hematologic, gastroin-
testinal, cerebrovascular, or immune system disorder.
Study design and treatment
Patients were randomly assigned to receive open-label
MF-DPI 400 mg administered QD either in the evening or
morning for 12 weeks. The primary objective of the study
was to compare the change from baseline in nighttime and
daytime asthma symptoms with morning versus evening
administration of MF-DPI 400 mg QD in order to establish
the more effective dose. The secondary objectives were to
assess the differences between the 2 regimens for treatment
adherence, patient device evaluations, and number of puffs
of rescue medication. A substudy was performed at certain
sites to assess the 24-h urinary cortisol area under the curve
(AUC) values and differential white blood cell counts.
Assessments
Patients visited the clinic on day 1 (baseline) and at weeks 4
and 12. Those patients participating in the substudy to
Enrolled
N=1568
MF-DPI 400 µg QD
Morning dosing
n=788
Randomized
n=1537
MF-DPI 400 µg QD
Evening dosing
n=749
Discontinued
n=87 
Discontinued
n=90
Completed
n=701
Completed
n=659
Figure 1 Patient disposition. MF-DPIZmometasone furoate
administered via a dry powder inhalation; QDZ once-daily.
Table 1 Patient demographics and previous ICS use
MF-DPI 400 mg
Morning
(nZ 788)
Evening
(nZ 749)
Age, y
Mean (SD) 49 (15) 49 (16)
Range 18e81 18e84
Sex, n (%)
Men 271 (34) 255 (34)
Women 517 (66) 494 (66)
Previous ICS use, n (%)
Beclomethasone 75 (10) 66 (9)
Budesonide 337 (45) 313 (44)
Fluticasone 96 (13) 92 (13)
Fluticasone/salmeterol 131 (18) 132 (18)
Budesonide/formoterol 106 (14) 113 (16)
ICSZ inhaled corticosteroid; MF-DPIZmometasone furoate
administered via a dry powder inhaler; SDZ standard deviation.
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counts also visited the clinic on days 2 and 3. During the
study, the patients rated their asthma symptoms in a diary
every morning and evening according to a 4-point scale
(daytime: 0Z not present to 3Z very marked and disturb-
ing; nighttime: 0Z slept through the night to 3Z kept
awake most/all night). Use of concomitant medication,
dosing time, and morning and evening PEF were also
recorded in the patient diaries. PEF was recorded only
when symptoms were apparent (score 2e3).
Patients were allowed to use their regular b2-agonists
(long-acting or short-acting) as rescue medication during
the study, and the use of rescue medication was also noted
in the diary. Use of 12 or more inhalations of the b2-agonist
on 2 consecutive days was to be considered as treatment
failure, and the study was supposed to be terminated for
that particular patient. The effect of concomitant b2-ago-
nist use on symptoms was not evaluated. Use of the inhaler
device was evaluated according to patients’ responses to
assess the ease of use and satisfaction. Response to therapy
was evaluated by the investigator by comparing the levels
of symptoms at the end and beginning of the study
according to a 5-point scale (1Zmuch worse to 5Zmuch
improved). Adherence to the treatment regimen and
adverse events were assessed at weeks 4 and 12.
Statistical analyses
Data sets included the safety population (patients who took
at least 1 dose of study medication), the intent-to-treat
(ITT) population (patients who took at least 1 dose of study
medication and had post-baseline efficacy information),
and the efficacy population (the ITT population excluding
patients with major protocol violations). Analysis of vari-
ance (ANOVA) was used to evaluate the change in symptom
score from baseline to the end of treatment. Equivalence of
the morning and evening treatment regimens was evalu-
ated using 95% confidence intervals (CIs) for the differences
in effects on nighttime and daytime symptoms with the 2
treatments. Equivalence was established if the 95% CIs
were within 0.25 of each other. Compliance was analyzed
using the Wilcoxon rank sum test. Summary statistics for
the number of puffs of rescue medication taken over the
treatment period were assessed using an ANOVA. Urine
cortisol AUC values and differential white cell count were
summarized by treatment group. Response to therapy and
device evaluation were analyzed using the Cochrane
ManteleHaenszel test.
Results
Of the 1568 patients enrolled, 1537 were randomly assigned
to treatment, and 1360 completed the study (Fig. 1). A to-
tal of 177 (11.5%) patients discontinued the study, mostly
because of adverse events (nZ 106; 6.9%), protocol viola-
tions (nZ 27; 1.8%), withdrawal of consent (nZ 23;
1.5%), and loss to follow up (nZ 12; 0.8%). The major pro-
tocol violations included no efficacy data recorded on diary
during week 12 of the study, misrandomized patients,
patients taking oral corticosteroids, or an ICS other than
MF-DPI during the study, and patients taking <70% of therequired number of doses of MF-DPI. A total of 545 patients
were excluded from the efficacy analysis because of major
protocol violations. The efficacy population (QD AM,
nZ 543; QD PM, nZ 479) was used for the primary analy-
sis. The treatment groups were well matched at baseline
(Table 1), and there were no differences between the
morning and evening dosing groups in the use of concomi-
tant b2-agonist medications during the study.
Efficacy
For those patients included in the efficacy analysis, asthma
symptoms at week 12 significantly improved from baseline
with either morning or evening administration of MF-DPI
400 mg QD (P< 0.0001). The mean improvements from base-
line in daytime symptom scores at week 12 with morning and
evening administration of MF-DPI 400 mg were 0.11 0.59
and 0.12 0.68, respectively (95% CI, 0.095 to 0.061)
and the corresponding improvements in nighttime symptom
scores were 0.08 0.59 and 0.07 0.50, respectively
(95% CI, 0.067 to 0.068) (Fig. 2). Equivalence was
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tween the treatment schedules in the efficacy populations
(Fig. 3). Equivalence was also demonstrated in daytime and
nighttime symptoms in the ITT population as the 95% CI for
treatment difference was within the equivalence range of
0.25.
Investigator-assessed improvement (‘‘improved’’ or
‘‘much improved’’) in response to MF-DPI therapy was
reported in 29e34% of patients, while 55e59% were
maintained (‘‘no change’’) in both the morning and evening
dosing groups, and for both the efficacy and ITT popula-
tions. The majority of patients (nZ 436) in the efficacy
population were previously on budesonide therapy
(Fig. 4). No significant differences in response to therapy
were detected between the morning and evening dosing
groups in either the ITT or the efficacy populations overall,
or by previous ICS use. Mean use of rescue medication was
the same in both treatment groups (1.2 puffs/day).Figure 3 Mean change (SEM) in daytime (A) and nighttime
(B) asthma symptom scores by week of treatment with once-
daily MF-DPI 400 mg. Negative change in symptom scores repre-
sents improvement.Treatment adherence and device evaluation
About 6% and 10% of patients in both the MF-DPI 400 mg QD
morning and evening treatment groups were classified as
having low or non-adherence at weeks 4 and 12,
respectively.
The majority of patients (95.6%) in the study found the
inhaler device to be ‘‘very easy’’ (70.2%) or ‘‘easy’’ (25.4%)
to use. In addition, 85.8% of patients who were asked about
inhaler device satisfaction ‘‘liked it’’ (47.8%) or ‘‘liked it
a lot’’ (38%) and 76.6% would like the inhaler device to be
prescribed to them in the future.
Safety
Overall, the adverse event profiles were similar for both
MF-DPI treatment groups (Table 2). No deaths were re-
ported in the study. In the safety population (nZ 1554),
57% of patients reported an adverse event. Thirty-nine per-
cent of patients reported adverse events that were unre-
lated to study treatment, 32% of patients reported
adverse events of mild severity, and 2% of patients reported
serious adverse events. The most frequent adverse events
were headache (16%), nasopharyngitis (11%), and asthma
(6%) (Table 2). Oral candidiasis was reported in 14 (1%)
patients.Figure 2 Mean change (SEM) from baseline in asthma symp-
tom scores at week 12. Negative change in symptom scores
represents improvement.Urinary cortisol levels and differential
white blood cell counts
The 24-h urinary cortisol value was below the reference
range (70e450 nmol/24 h) at 1 or more visits in 18 patients
receiving morning dosing and 19 patients receiving evening
dosing. These levels were considered to be clinically rele-
vant in 4 and 7 patients in the morning and evening dosing
groups, respectively.
In the morning dosing group, 23 patients had differen-
tial white cell counts outside the reference range at 1 or
more visits, and these were considered to be clinically
relevant in 3 patients. In the evening dosing group, 24
patients had differential white cell counts outside the
reference range at 1 or more visits, however, these were
not considered to be clinically relevant. In both dosing
groups, eosinophil counts outside the reference range were
more common than other white cell counts outside the
reference range.
Overall, MF-DPI 400 mg QD did not appear to have an ad-
verse effect on the 24-h urinary cortisol AUC values or
white cell counts, and there were no differences in the
morning or evening dosing groups on these parameters.
Discussion
In this open-label study, administration of MF-DPI 400 mg QD
in the evening had effects similar to MF-DPI 400 mg QD
Table 2 Adverse events
MF-DPI 400 mg
Morning dosing,
n(%) (nZ 796)
Evening dosing,
n(%) (nZ 758)
Any adverse event 462 (58) 417 (55)
Causality
Related 127 (16) 140 (19)
Not related 335 (42) 277 (37)
Severity
Mild 270 (34) 231 (31)
Moderate 171 (22) 170 (22)
Severe 21 (3) 16 (2)
Leading to
discontinuation
48 (6) 56 (7)
Serious adverse events 16 (2) 14 (2)
Deaths 0 0
Most commonly
reported adverse
events
Nasopharyngitis 88 (11) 86 (11)
Headache 130 (16) 117 (15)
Asthma 50 (6) 50 (7)
MF-DPIZmometasone furoate administered via a dry powder
inhaler.
Figure 4 Investigator-assessed improvement in daytime (A)
and nighttime (B) asthma symptoms by previous inhaled cortico-
steroid use. Negative values represent increases in symptoms.
There were no mean changes in daytime or nighttime symptoms
in theeveningdosing groupofpatientswhowerepreviously using
FP. BDPZ beclomethasone (nZ 99); BUDZ budesonide
(nZ 436); FPZ fluticasone (nZ 128); FP/SALZ fluticaso-
neþ salmeterol combination (nZ 164); BUD/FORZ budesoni-
deþ formoterol combination (nZ 133); unknown (nZ 59).
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mild to moderate asthma. Both the evening and morning
dosing regimens provided the same level of 24-hour symp-
tom control, as shown by similar reductions from baseline
in daytime and nighttime symptoms. Overall, differences
between morning and evening regimens were not detected
with this open-label investigation as the 95% CIs were
entirely within the prestated 0.25% interval. Treatment
adherence was high in both groups, suggesting that QD
administration promoted adherence. Patient acceptance
of the device was high, with the majority expressing their
desire to use the device in the future. MF-DPI 400 mg QD
was well tolerated, and adverse events were similar in
both treatment groups. HPA axis effects were minimal, as
indicated by urinary cortisol levels.
In addition to its open-label design, this study has
several other limitations. Firstly, the primary efficacy
outcome was evaluated using patient-rated symptoms,
a subjective measure that may have biased the results.
Secondly, the effect of concomitant b2-agonist use on
symptoms was not assessed, and patients were allowed
to use long-acting b2-agonists as rescue medication.Whereas this may be possible with formoterol because of
its rapid onset of action,13 it is not possible with salme-
terol. Additionally, as many as 40% of the trial population
violated the protocol or discontinued, thus limiting the
assessments to a much smaller efficacy population
(nZ 1022) rather than the ITT population (nZ 1537). In
light of these limitations, the results of this trial should
be interpreted with caution. These results also highlight
the limitations of patient-reported subjective efficacy
measurements since several placebo-controlled studies
that characterized MF-DPI QD AM and QD PM dosing using
objective measures, such as FEV1, showed that evening
QD dosing with MF-DPI improved FEV1 to a greater extent
than morning dosing.10,14 In those studies, QD evening dos-
ing regimens of MF-DPI were found to be associated with
similar efficacy as that of twice-daily MF-DPI.10,11,15 These
findings suggest that the absence of differences between
the therapeutic effects of QD PM and AM dosing may in
fact be the result of limitations in the specificity of the
patient-reported metrics further enhanced by the large
number of patients excluded from the efficacy analysis
because of protocol violations.
In conclusion, this open-label study did not identify
differences between morning and evening dosing of MF-DPI
400 mg QD; however, evidence from double-blind, placebo-
controlled studies described in detail elsewhere suggests
that evening dosing of MF-DPI QD achieves better outcomes
than morning dosing.
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